Patents by Inventor Junji Kanazawa
Junji Kanazawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9675625Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: GrantFiled: June 17, 2013Date of Patent: June 13, 2017Assignee: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sakai, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Publication number: 20130295045Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: ApplicationFiled: June 17, 2013Publication date: November 7, 2013Inventors: Kenya SHITARA, Rinpei NIWA, So OHTA, Yuka SASAKI, Junji KANAZAWA, Toshihiko ISHII, Shiro AKINAGA
-
Patent number: 8491902Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: GrantFiled: December 3, 2004Date of Patent: July 23, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sasaki, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Publication number: 20090226399Abstract: In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.Type: ApplicationFiled: April 8, 2009Publication date: September 10, 2009Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, Junji Kanazawa, Masao Asada
-
Publication number: 20080166345Abstract: In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.Type: ApplicationFiled: February 19, 2008Publication date: July 10, 2008Applicant: KYOWA HAKKO KOGYO CO., LTD.Inventors: Kenya SHITARA, Rinpei Niwa, Junji Kanazawa, Masao Asada
-
Publication number: 20070020263Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: ApplicationFiled: December 3, 2004Publication date: January 25, 2007Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sasaki, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Publication number: 20050260206Abstract: In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.Type: ApplicationFiled: March 29, 2002Publication date: November 24, 2005Inventors: Kenya Shitara, Rinpei Niwa, Junji Kanazawa, Masao Asada
-
Patent number: 6548536Abstract: Agents for inducing apoptosis comprising a tetrocarcin derivative represented by the following formula (I) or a salt thereof as an active ingredient (---- represents a single bond or a double bond; j and k represent 0 or 1; R1 to R3, R7 to R10 and R14 represent a hydrogen atom, a lower alkyl group and the like; R4, R11, R12, R13 and R15 to R18 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like; R5 and R6 represents a hydrogen atom, a hydroxyl group, a lower alkyl group, a group represented by the following formula (B) (R32 represents a formyl group and the like, R33 to R35 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like); R19 represents a hydroxyl group, a lower alkoxyl group, a lower alkanoyloxy group and the like). The agents are useful as medicaments for preventive and/or therapeutic treatment of diseases resulting from increased expression of Bcl-2 family proteins, for example, cancers, AIDS and the like.Type: GrantFiled: February 27, 2001Date of Patent: April 15, 2003Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Mitsunobu Hara, Takayuki Nakashima, Yutaka Kanda, Masami Hamano, Shun-ichi Ikeda, Yuko Uosaki, Yoko Takata, Junji Kanazawa
-
Publication number: 20020022598Abstract: Agents for inducing apoptosis comprising a tetrocarcin derivative represented by the following formula (I) or a salt thereof as an active ingredient (- - - - represents a single bond or a double bond; j and k represent 0 or 1; R1 to R3, R7 to R10 and R14 represent a hydrogen atom, a lower alkyl group and the like; R4, R11, R12, R13 and R15 to R18 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like; R5 and R6 represents a hydrogen atom, a hydroxyl group, a lower alkyl group, a group represented by the following formula (B) (R32 represents a formyl group and the like, R33 to R35 represent a hydrogen atom, a hydroxyl group, a lower alkyl group and the like); R19 represents a hydroxyl group, a lower alkoxyl group, a lower alkanoyloxy group and the like). The agents are useful as medicaments for preventive and/or therapeutic treatment of diseases resulting from increased expression of Bcl-2 family proteins, for example, cancers, AIDS and the like.Type: ApplicationFiled: February 27, 2001Publication date: February 21, 2002Applicant: KYOWA HAKKO KOGYO CO., LTDInventors: Mitsunobu Hara, Takayuki Nakashima, Yutaka Kanda, Masami Hamano, Shun-ichi Ikeda, Yuko Uosaki, Yoko Takata, Junji Kanazawa
-
Patent number: 5952355Abstract: The present invention relates to propenone derivatives represented by the following formula (I): ##STR1## wherein R.sup.1 represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, or YR.sup.5 (wherein Y represents S or O; and R.sup.5 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or a substituted or unsubstituted cyclic ether residue); R.sup.2 and R.sup.3 independently represent hydrogen, lower alkyl, or substituted or unsubstituted aralkyl, or alternatively R.sup.2 and R.sup.3 are combined to form substituted or unsubstituted methylene or ethylene; R.sup.4 represents hydrogen, hydroxy, lower alkyl, substituted or unsubstituted aralkyl, lower alkoxy, substituted or unsubstituted aralkyloxy, or halogen; and X represents substituted or unsubstituted indolyl; or pharmaceutically acceptable salts thereof.Type: GrantFiled: November 26, 1996Date of Patent: September 14, 1999Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Shun-Ichi Ikeda, Uichiro Kimura, Tadashi Ashizawa, Katsushige Gomi, Hiromitsu Saito, Masaji Kasai, Junji Kanazawa, Kimihito Sasaki, Etsuko Nukui, Masami Okabe, Soichiro Sato